Boulevard Bio launched from stealth with $65 million in funding led by Deerfield Management, positioning the company to develop targeted autoimmune immunotherapies built around immune reset biology. The startup is advancing a trio of antibody programs, including BLVD101 for IgA nephropathy, targeting BAFF/APRIL signaling. Caribou Biosciences outlined plans to widen access to allogeneic CAR T by moving toward a pivotal Phase III study. The company said its chRDNA genome-editing strategy and donor-selection approach, including use of donors under age 30 and HLA matching from inventory, are designed to deliver durable responses with an off-the-shelf manufacturing model. Both events address the same bottleneck from different angles—scaling access and dosing practicality for immune-mediated diseases.